Entera Bio Ltd. (NASDAQ:ENTX) Stock Has Consensus Target Price of $9.60 According to Brokerages

Shares of Entera Bio Ltd. (NASDAQ:ENTX) have earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $9.60.

ENTX has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a research note on Saturday, August 8th. Cantor Fitzgerald began coverage on shares of Entera Bio in a research report on Tuesday, September 22nd. They set an “overweight” rating on the stock. Leerink Partners initiated coverage on shares of Entera Bio in a research note on Friday, September 18th. They set an “outperform” rating and a $9.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Entera Bio in a report on Thursday, October 15th. Finally, Guggenheim began coverage on shares of Entera Bio in a report on Thursday, September 24th. They issued a “buy” rating and a $11.00 price target for the company.

Entera Bio Stock Performance

Shares of ENTX stock opened at $2.92 on Monday. The company has a market cap of $507.85 million, a P/E ratio of -8.34 and a beta of 1.40. The stock has a 50 day simple moving average of $2.89 and a two-hundred day simple moving average of $2.09. Entera Bio has a fifty-two week low of $0.91 and a fifty-two week high of $4.20.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). On average, research analysts predict that Entera Bio will post -0.40 earnings per share for the current year.

Hedge Funds Weigh In On Entera Bio

An institutional investor recently raised its stake in Entera Bio stock. Seven Fleet Capital Management LP lifted its stake in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 51.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 205,542 shares of the company’s stock after purchasing an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned about 0.42% of Entera Bio worth $228,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.